Veltuzumab

TUESDAY, March 10, 2026 -- For patients with systemic lupus erythematosus (SLE), obinutuzumab , a glycoengineered type II anti-CD20 monoclonal antibody, is superior to placebo, according to a study published online March 6 in the New England Journal of Medicine . Richard A. Furie, M.D., from Northwell in New Hyde Park, New York, and colleagues conducted a phase 3 trial involving adults with active SLE without proliferative or membranous lupus nephritis who were receiving standard therapy. Patients were randomly assigned to receive obinutuzumab (1,000 mg) or placebo on day 1 and weeks 2, 24, and 26 (151 and 152 patients, respectively). A response on the SLE Responder Index 4 (SRI-4) was the primary end point at week 52 in the prespecified analysis. The researchers found an SRI-4 response in 76.7 and 53.5 percent of patients in the obinutuzumab and placebo groups, respectively, at week 52. In an additional analysis where response status was not affected by nonfatal intercurrent events, the corresponding percentages were 85.4 and 68.5 percent. With respect to all key secondary end points, obinutuzumab was superior to placebo. Adverse events were reported in 88.7 and 81.5 percent of those in the obinutuzumab and placebo groups, respectively, and serious adverse events were reported in 15.9 and 11.9 percent, respectively. During the double-blind period, one patient in the obinutuzumab group and three in the placebo group died. "These findings complement those of the phase 3 REGENCY trial involving patients with active proliferative lupus nephritis, whereby treatment with obinutuzumab led to clinically meaningful improvements," the authors write. Several authors disclosed ties to biopharmaceutical companies, including F. Hoffmann La Roche, which manufactures obinutuzumab and funded the study. Abstract/Full Text (subscription or payment may be required)

TOKYO, February 19, 2026 -- Zenyaku Kogyo Co., Ltd. (website in Japanese only) and Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Zenyaku obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW), for an additional indication of an anti-CD20 monoclonal antibody Rituxan® intravenous injection 100 mg and 500 mg [generic name: rituximab (genetical recombination)] (hereafter “Rituxan”), which is co-marketed by both companies, for the treatment of autoimmune hemolytic anemia. The Japanese Society of Hematology and the Japanese Society of Pediatric Hematology/Oncology submitted development requests for an additional indication for Rituxan for autoimmune hemolytic anemia (hereafter “AIHA”). The request was evaluated and deemed to qualify for a public knowledge-based application at the “64th Evaluation Committee on unapproved or off-label drugs with high medical needs” held on July 4, 2025. It was officially decided that a public knowledge-based application could be submitted at the “Pharmaceutical Affairs Council’s First Committee on Drugs” held on July 31, 2025. In response to this, Zenyaku submitted a public knowledge-based application on August 29, 2025, and has now obtained approval. AIHA is a collective term for immune hemolytic anemia caused by the acquired production of autoantibodies that react with antigens on red blood cell membranes, resulting in the destruction (hemolysis) of red blood cells through antigen-antibody reactions and a markedly shortened red blood cell lifespan1). It is designated as an intractable disease by the Japanese government (designated intractable disease No. 61). AIHA is broadly classified into warm AIHA, where autoantibodies react near body temperature (37°C), and cold AIHA [cold agglutinin disease (hereafter “CAD”) and paroxysmal cold hemoglobinuria (hereafter “PCH”)], which react at temperatures below body temperature1). In all types, factors such as infection, immunodeficiency, immune system dysregulation, hormonal environment, drugs, and tumors are considered to be involved in the etiology of AIHA1). In the treatment of AIHA, approximately 80% of warm AIHA patients show improvement with adrenocortical steroids; however, recurrence is common and long-term administration is necessary, and for relapsed or refractory cases, splenectomy has been performed1). In CAD patients, maintaining warmth is the most basic treatment, but severe symptoms such as anemia, transfusion dependence, and peripheral circulatory disorders may occur1)2). Japanese and international clinical practice guidelines1)2) recommend Rituxan therapy as one of the treatment options for such patients. PCH is a rare type, mainly observed in young children following viral infections, and is generally treated with warmth maintenance and adrenocortical steroids. Nonetheless, reports suggest the efficacy of Rituxan in chronic patients or in patients who are refractory to adrenocortical steroid therapy1)3). Rituxan is an anti-CD20 monoclonal antibody that specifically binds to CD20, a protein expressed on B cells, excluding hematopoietic stem cells and plasma cells. It attacks and damages target B cells by leveraging the human body’s own immune system. B cells ultimately differentiate into antibody-producing plasma cells, but in diseases involving autoantibodies, it is believed that autoreactive B cells are activated and differentiated for some reason, leading to the proliferation of plasma cells that produce autoantibodies4)5). Although the etiology leading to the activation of autoreactive B cells and the appearance of autoantibodies in AIHA has not been fully elucidated, the common presence of autoantibodies in both warm and cold AIHA1) suggests that therapeutic effects through B cell depletion by Rituxan can be expected. Zenyaku and Chugai are committed to working closely together to ensure that Rituxan can further contribute to the treatment of patients with autoimmune hemolytic anemia. Trademarks used or mentioned in this release are protected by law. Sources Working Group for Revision of Diagnostic Criteria and Clinical Reference Guide for Autoimmune Hemolytic Anemia, Research Group on Idiopathic Hematopoietic Disorders, Research Project on Intractable Diseases, Health and Labour Sciences Research Grants. Clinical Reference Guide for Autoimmune Hemolytic Anemia (2023 Revised Edition). In Japanese only: https://zoketsushogaihan.umin.jp/file/2022/Autoimmune_hemolytic_anemia.pdf Hill QA, Stamps R, Massey E, et al. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol 2017; 176(3): 395-411. Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev 2020; 41: 100648. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006; 5(7): 564-576. Schett G, Nagy G, Krönke G, Mielenz D. B-cell depletion in autoimmune diseases. Ann Rheum Dis 2024; 83(11): 1409-1420.